RIGL
Income statement / Annual
Last year (2024), Rigel Pharmaceuticals, Inc.'s total revenue was $179.28 M,
an increase of 53.38% from the previous year.
In 2024, Rigel Pharmaceuticals, Inc.'s net income was $17.49 M.
See Rigel Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$179.28 M |
$116.88 M |
$120.24 M |
$149.24 M |
$108.62 M |
$59.29 M |
$44.51 M |
$4.48 M |
$20.38 M |
$28.90 M |
| Cost of Revenue |
$18.65 M
|
$7.11 M
|
$1.75 M
|
$1.08 M
|
$895,000.00
|
$906,000.00
|
$287,000.00
|
$46.27 M
|
$63.45 M
|
$62.83 M
|
| Gross Profit |
$160.63 M
|
$109.77 M
|
$118.49 M
|
$148.15 M
|
$107.73 M
|
$58.38 M
|
$44.22 M
|
-$41.79 M
|
-$43.06 M
|
-$33.93 M
|
| Gross Profit Ratio |
0.9
|
0.94
|
0.99
|
0.99
|
0.99
|
0.98
|
0.99
|
-9.32
|
-2.11
|
-1.17
|
| Research and Development Expenses |
$23.38 M
|
$24.52 M
|
$60.27 M
|
$65.24 M
|
$60.10 M
|
$52.89 M
|
$46.90 M
|
$46.27 M
|
$63.45 M
|
$62.83 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$70.00 M
|
$37.83 M
|
$20.91 M
|
$17.81 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$113.06 M
|
$105.74 M
|
$112.45 M
|
$91.89 M
|
$76.60 M
|
$74.59 M
|
$70.00 M
|
$37.83 M
|
$20.91 M
|
$17.81 M
|
| Other Expenses |
$0.00
|
$0.00
|
$1.32 M
|
$3.52 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$136.44 M
|
$130.26 M
|
$172.72 M
|
$157.13 M
|
$136.70 M
|
$127.47 M
|
$116.91 M
|
$84.10 M
|
$84.35 M
|
$80.64 M
|
| Cost And Expenses |
$155.09 M
|
$137.37 M
|
$174.47 M
|
$158.21 M
|
$137.59 M
|
$128.38 M
|
$117.19 M
|
$84.10 M
|
$84.35 M
|
$80.64 M
|
| Interest Income |
$2.09 M
|
$2.27 M
|
$684,000.00
|
$47,000.00
|
$582,000.00
|
$2.53 M
|
$2.20 M
|
$892,000.00
|
$437,000.00
|
$222,000.00
|
| Interest Expense |
$7.92 M
|
$6.87 M
|
$3.71 M
|
$4.86 M
|
$1.35 M
|
$335,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$2.23 M
|
$1.24 M
|
$998,000.00
|
$1.16 M
|
$706,000.00
|
$683,000.00
|
$594,000.00
|
$465,000.00
|
$941,000.00
|
$1.44 M
|
| EBITDA |
$28.51 M |
-$16.98 M |
-$53.87 M |
-$11.29 M |
-$27.69 M |
-$65.88 M |
-$69.89 M |
-$77.53 M |
-$63.03 M |
-$50.30 M |
| EBITDA Ratio |
0.16
|
-0.15
|
-0.45
|
-0.06
|
-0.26
|
-1.12
|
-1.63
|
-17.92
|
-2.86
|
-1.79
|
| Operating Income Ratio |
0.13
|
-0.18
|
-0.45
|
-0.06
|
-0.27
|
-1.17
|
-1.63
|
-17.76
|
-3.42
|
-1.79
|
| Total Other Income/Expenses Net |
-$5.83 M
|
-$4.60 M
|
-$3.02 M
|
-$4.81 M
|
-$771,000.00
|
$2.20 M
|
$2.20 M
|
$1.62 M
|
$525,000.00
|
$279,000.00
|
| Income Before Tax |
$18.37 M
|
-$25.09 M
|
-$58.57 M
|
-$17.31 M
|
-$29.74 M
|
-$66.89 M
|
-$70.48 M
|
-$77.99 M
|
-$69.22 M
|
-$51.46 M
|
| Income Before Tax Ratio |
0.1
|
-0.21
|
-0.49
|
-0.12
|
-0.27
|
-1.13
|
-1.58
|
-17.39
|
-3.4
|
-1.78
|
| Income Tax Expense |
$881,000.00
|
$0.00
|
$3.02 M
|
$605,000.00
|
$647,000.00
|
-$348,000.00
|
$2.20 M
|
-$2.09 M
|
$4.30 M
|
-$1.72 M
|
| Net Income |
$17.49 M
|
-$25.09 M
|
-$61.60 M
|
-$17.91 M
|
-$30.39 M
|
-$66.55 M
|
-$70.48 M
|
-$77.99 M
|
-$69.22 M
|
-$51.46 M
|
| Net Income Ratio |
0.1
|
-0.21
|
-0.51
|
-0.12
|
-0.28
|
-1.12
|
-1.58
|
-17.39
|
-3.4
|
-1.78
|
| EPS |
0.99 |
-1.44 |
-3.4 |
-1.05 |
-1.76 |
-4 |
-4.39 |
-6.17 |
-7.33 |
-5.82 |
| EPS Diluted |
0.99 |
-1.44 |
-3.4 |
-1.05 |
-1.76 |
-4 |
-4.39 |
-6.17 |
-7.33 |
-5.82 |
| Weighted Average Shares Out |
$17.58 M
|
$17.40 M
|
$17.24 M
|
$17.05 M
|
$16.88 M
|
$16.72 M
|
$16.05 M
|
$12.63 M
|
$9.44 M
|
$8.84 M
|
| Weighted Average Shares Out Diluted |
$17.69 M
|
$17.40 M
|
$17.24 M
|
$17.05 M
|
$16.88 M
|
$16.74 M
|
$16.05 M
|
$12.63 M
|
$9.44 M
|
$8.84 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
